Vioxx

Vioxx
IUPAC name	4-[4-(methylsulfonyl)phenyl]-3-phenyl-5H-furan-2-one
Tradename	Vioxx
Drugs.com	Monograph
MedlinePlus	a699047
Licence US	Merck & Co.
Routes of administration	Oral
CAS number	162011-90-7
ATC prefix	M01
ATC suffix	AH02
PubChem	5090
DrugBank	DB00533
ChemSpiderID	4910
UNII	0QTW8Z7MCR
ChEMBL	35
Synonyms	MK-0966
Molecular formula	C17H14O4S
Melting point	203–205 °C
Bioavailability	93%
Protein bound	87%
Metabolism	Hepatic (CYP2C9 minor)
Elimination half-life	17 hours
Excretion	Urine (72%), feces (14%)

Vioxx. Vioxx was a nonsteroidal anti-inflammatory drug developed by Merck & Co. and approved by the Food and Drug Administration in 1999 for the management of osteoarthritis, acute pain, and dysmenorrhea. It gained rapid popularity as a selective cyclooxygenase-2 inhibitor, marketed for its reduced gastrointestinal toxicity compared to traditional NSAIDs like naproxen and ibuprofen. The drug was voluntarily withdrawn worldwide in 2004 following evidence linking its long-term use to an increased risk of serious cardiovascular events, including myocardial infarction and stroke.

History and development

The development of Vioxx began in the 1990s as part of a broader pharmaceutical industry effort to create safer anti-inflammatory agents. Researchers at Merck & Co. sought to inhibit the cyclooxygenase-2 enzyme responsible for inflammation and pain while sparing the cyclooxygenase-1 enzyme, which protects the gastric mucosa. The compound, known internally as MK-0966, emerged from this research program. Following extensive clinical trials, the drug received approval from the Food and Drug Administration in May 1999, with subsequent approvals from regulatory bodies like the European Medicines Agency. Its launch was supported by a major direct-to-consumer advertising campaign, making it one of the most prescribed drugs in the United States.

Mechanism of action

Vioxx functions as a selective and potent inhibitor of the cyclooxygenase-2 enzyme. This isoenzyme is induced at sites of inflammation by cytokines and growth factors, playing a key role in synthesizing prostaglandins that mediate pain, fever, and swelling. By selectively blocking cyclooxygenase-2, Vioxx reduces the production of these inflammatory prostaglandins without significantly inhibiting cyclooxygenase-1. The cyclooxygenase-1 enzyme is constitutively expressed in tissues like the gastrointestinal tract and platelets, where it supports protective functions such as maintaining gastric mucosal integrity and normal platelet aggregation. This theoretical selectivity formed the basis for its improved gastrointestinal safety profile compared to non-selective NSAIDs.

Clinical use and efficacy

Vioxx was indicated for the relief of signs and symptoms of osteoarthritis, the management of acute pain in adults, and the treatment of primary dysmenorrhea. In clinical studies such as the VIGOR trial, it demonstrated significant efficacy in reducing pain and improving function in patients with rheumatoid arthritis, showing superior gastrointestinal tolerability compared to naproxen. It was also evaluated for potential use in conditions like Alzheimer's disease, though such applications were not approved. The drug was typically administered once daily due to its long elimination half-life, which provided sustained analgesic and anti-inflammatory effects, contributing to its widespread patient acceptance and strong market performance.

Safety concerns and withdrawal

Concerns about the cardiovascular safety of Vioxx emerged from the VIGOR trial, published in the New England Journal of Medicine in 2000, which showed a higher incidence of myocardial infarction among patients taking the drug compared to those on naproxen. Subsequent studies, including the APPROVe trial, which was designed to evaluate its efficacy in preventing colorectal adenomas, confirmed a significant increased risk of thrombotic events after 18 months of use. Faced with this accumulating evidence, Merck & Co. announced a voluntary worldwide withdrawal of Vioxx on September 30, 2004. The decision was coordinated with the Food and Drug Administration and other global regulators like the Therapeutic Goods Administration in Australia.

Legal and regulatory impact

The withdrawal of Vioxx triggered one of the largest litigation events in pharmaceutical history, with Merck & Co. facing tens of thousands of lawsuits from patients and their families. These legal proceedings, consolidated in jurisdictions like the District Court for the Eastern District of Louisiana, alleged that the company failed to adequately warn of cardiovascular risks. Merck ultimately established a multi-billion dollar settlement fund to resolve claims. The case profoundly impacted the Food and Drug Administration, leading to congressional hearings, criticism of its Drug Safety oversight, and the eventual creation of the FDA Adverse Event Reporting System and more stringent post-marketing surveillance requirements under acts like the FDA Amendments Act of 2007.

Legacy and subsequent research

The Vioxx episode serves as a landmark case study in pharmacovigilance, drug safety, and medical ethics. It underscored the critical importance of long-term cardiovascular safety trials for new anti-inflammatory drugs and exposed weaknesses in post-marketing surveillance systems. The controversy accelerated research into the cardiovascular biology of cyclooxygenase-2 inhibition and influenced the development and labeling of subsequent COX-2 inhibitors like celecoxib. It also fueled ongoing debates about conflict of interest in clinical research, the role of direct-to-consumer advertising, and the balance between regulatory approval and ongoing risk assessment. The case remains a pivotal reference in the curricula of medical schools and public health institutions worldwide.

Category:Drugs withdrawn from the market Category:Nonsteroidal anti-inflammatory drugs Category:Merck & Co.